BR112016030577A2 - vacinas contra o vírus da gripe e usos das mesmas - Google Patents

vacinas contra o vírus da gripe e usos das mesmas

Info

Publication number
BR112016030577A2
BR112016030577A2 BR112016030577A BR112016030577A BR112016030577A2 BR 112016030577 A2 BR112016030577 A2 BR 112016030577A2 BR 112016030577 A BR112016030577 A BR 112016030577A BR 112016030577 A BR112016030577 A BR 112016030577A BR 112016030577 A2 BR112016030577 A2 BR 112016030577A2
Authority
BR
Brazil
Prior art keywords
influenza vaccines
methods
same
stem domain
domain polypeptides
Prior art date
Application number
BR112016030577A
Other languages
English (en)
Other versions
BR112016030577A8 (pt
Inventor
Impagliazzo Antonietta
Wilem Meijberg Jan
Radosevic Katarina
Wagner Michelle
Ding Zhaoqing
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016030577(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of BR112016030577A2 publication Critical patent/BR112016030577A2/pt
Publication of BR112016030577A8 publication Critical patent/BR112016030577A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/11Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

são fornecidos aqui polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, métodos para proporcionar poli-peptídeos do domínio de haste da hemaglutinina, composições compreendendo os mesmos, vacinas compreendendo os mesmos e métodos de seu uso, em particular na detecção, prevenção e/ou tratamento da gripe.
BR112016030577A 2014-07-10 2015-07-09 polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes BR112016030577A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14176459 2014-07-10
US201462062754P 2014-10-10 2014-10-10
EP14195143 2014-11-27
EP15155761 2015-02-19
PCT/EP2015/065663 WO2016005482A1 (en) 2014-07-10 2015-07-09 Influenza virus vaccines and uses thereof

Publications (2)

Publication Number Publication Date
BR112016030577A2 true BR112016030577A2 (pt) 2017-10-31
BR112016030577A8 BR112016030577A8 (pt) 2021-07-20

Family

ID=55063616

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016030577A BR112016030577A8 (pt) 2014-07-10 2015-07-09 polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes

Country Status (17)

Country Link
US (1) US10117925B2 (pt)
EP (1) EP3166963B1 (pt)
JP (1) JP7094103B2 (pt)
KR (1) KR102463632B1 (pt)
CN (1) CN107074912B (pt)
AU (1) AU2015286723B2 (pt)
BR (1) BR112016030577A8 (pt)
CA (1) CA2953451C (pt)
CL (1) CL2017000064A1 (pt)
EA (1) EA035375B1 (pt)
MX (1) MX2017000395A (pt)
MY (1) MY182440A (pt)
PE (1) PE20170291A1 (pt)
PH (1) PH12016502468A1 (pt)
SG (1) SG11201610456UA (pt)
WO (1) WO2016005482A1 (pt)
ZA (1) ZA201700165B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
SG11201402633UA (en) 2011-11-28 2014-09-26 Crucell Holland Bv Influenza virus vaccines and uses thereof
US9968670B2 (en) 2012-12-18 2018-05-15 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
MX369317B (es) 2013-05-30 2019-11-05 Janssen Vaccines & Prevention Bv Vacunas contra el virus de la influenza y sus usos.
CN106661091B (zh) 2014-07-10 2020-10-30 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途
EP3247389A4 (en) 2015-01-23 2019-10-30 Icahn School of Medicine at Mount Sinai INFLUENZAVIRUSSCHUTZIMPFPLÄNE
CN109641041A (zh) 2016-06-15 2019-04-16 西奈山伊坎医学院 流感病毒血细胞凝集素蛋白及其用途
SG10201912944QA (en) * 2016-09-02 2020-02-27 The Usa As Represented By The Secretary Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
CN107765001B (zh) * 2017-10-24 2020-03-27 中国科学院苏州纳米技术与纳米仿生研究所 禽流感病毒感染或禽流感疫苗免疫分型试剂盒
JP7317047B2 (ja) 2018-01-23 2023-07-28 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザウイルスワクチン及びその使用
JP7329529B2 (ja) * 2018-03-28 2023-08-18 サノフィ パスツール インコーポレイテッド ヘマグルチニンを含む広範に防御的なワクチン組成物を生成する方法
TW202016308A (zh) * 2018-06-27 2020-05-01 加拿大商苜蓿股份有限公司 流感病毒血球凝集素突變體
CN109239355B (zh) * 2018-09-05 2020-08-25 中牧实业股份有限公司 禽流感病毒h9亚型抗体酶联免疫检测试剂盒
BR112021005255A2 (pt) 2018-09-21 2021-06-29 Board Of Regents Of The University Of Nebraska método de produção e uso de genes para vacina contra a influenza centralizada universal
KR20220057578A (ko) 2019-09-05 2022-05-09 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 백신 및 이의 용도
GB202004825D0 (en) * 2020-04-01 2020-05-13 Diosynvax Ltd Influenza vaccines
CA3190070A1 (en) * 2020-09-07 2022-03-10 Martijn Alexander LANGEREIS Ha stem vaccine for ha antibody-positive targets
TW202317600A (zh) * 2021-06-23 2023-05-01 潤惠生技股份有限公司 預防多種病毒感染的多價疫苗
WO2023154821A2 (en) * 2022-02-11 2023-08-17 University Of Washington Compositions comprising influenza hemagglutinin stem and method for enhancing cross-protective immunity
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
WO2024104947A2 (en) * 2022-11-14 2024-05-23 Janssen Vaccines & Prevention B.V. Influenza b virus vaccines and uses thereof
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007293662B2 (en) 2006-09-07 2012-10-04 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
JP2012521786A (ja) * 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
US8470327B2 (en) 2009-05-11 2013-06-25 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
CN102939103A (zh) * 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
WO2012054745A1 (en) * 2010-10-20 2012-04-26 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
CA2838999C (en) 2011-07-14 2021-02-16 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
SG11201402633UA (en) * 2011-11-28 2014-09-26 Crucell Holland Bv Influenza virus vaccines and uses thereof
MX369317B (es) 2013-05-30 2019-11-05 Janssen Vaccines & Prevention Bv Vacunas contra el virus de la influenza y sus usos.
CN106661091B (zh) 2014-07-10 2020-10-30 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途

Also Published As

Publication number Publication date
AU2015286723B2 (en) 2019-11-21
SG11201610456UA (en) 2017-01-27
AU2015286723A1 (en) 2017-01-12
MY182440A (en) 2021-01-25
CN107074912A (zh) 2017-08-18
JP2017521073A (ja) 2017-08-03
CA2953451C (en) 2023-09-19
CL2017000064A1 (es) 2017-11-10
CA2953451A1 (en) 2016-01-14
JP7094103B2 (ja) 2022-07-01
WO2016005482A1 (en) 2016-01-14
KR102463632B1 (ko) 2022-11-03
BR112016030577A8 (pt) 2021-07-20
US20170189519A1 (en) 2017-07-06
US10117925B2 (en) 2018-11-06
MX2017000395A (es) 2018-02-08
PH12016502468B1 (en) 2017-04-10
CN107074912B (zh) 2021-10-29
ZA201700165B (en) 2019-06-26
PE20170291A1 (es) 2017-03-26
EP3166963B1 (en) 2020-04-22
EP3166963A1 (en) 2017-05-17
EA035375B1 (ru) 2020-06-03
KR20170027846A (ko) 2017-03-10
PH12016502468A1 (en) 2017-04-10
EA201692467A1 (ru) 2017-05-31

Similar Documents

Publication Publication Date Title
BR112016030577A2 (pt) vacinas contra o vírus da gripe e usos das mesmas
BR112017000257A2 (pt) vacinas contra o vírus da gripe e usos das mesmas
SV2018005610A (es) Derivados de oxopiridina sustituidos
DK3559022T3 (da) Virulenssvækket bakteriebaseret proteinlevering
BR112015014482A2 (pt) vacinas para vírus influenza e seus usos
CL2016002123A1 (es) Nuevo polisacárido y usos del mismo
EA201792500A1 (ru) Aav-опосредованная экспрессия антител против гриппа и способы их использования
BR112016030787A2 (pt) entidade química, composição farmacêutica e seu uso
UY36021A (es) Proteìnas fc multimèricas
DK3121175T3 (da) 1,3-benzodioxolderivater som ezh1- og/eller ezh2-hæmmere
BR112016022062A2 (pt) Combinação, composição farmacêutica, uso de uma combinação ou de uma composição farmacêutica, e, produto farmacêutico
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112016030284A2 (pt) Formulações, seu uso ou produção de detergentes de lavagem de louça e sua produção
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
BR112015025748A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
BR112016026552A2 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
CL2020001901A1 (es) Vacunas contra virus de la gripe y usos de las mismas.
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
BR112016027383A2 (pt) Derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112016019868A2 (pt) proteínas de fusão tatk-cdkl5, composições, formulações, e seu uso
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
WO2014152946A3 (en) Polypeptides for treating and/or limiting influenza infection
BR112018004267A2 (pt) concentrado líquido para conservar cosméticos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.